JP2008501357A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501357A5
JP2008501357A5 JP2007526577A JP2007526577A JP2008501357A5 JP 2008501357 A5 JP2008501357 A5 JP 2008501357A5 JP 2007526577 A JP2007526577 A JP 2007526577A JP 2007526577 A JP2007526577 A JP 2007526577A JP 2008501357 A5 JP2008501357 A5 JP 2008501357A5
Authority
JP
Japan
Prior art keywords
human
genetically modified
human mammal
gene
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007526577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501357A (ja
Filing date
Publication date
Priority claimed from GBGB0412966.4A external-priority patent/GB0412966D0/en
Application filed filed Critical
Publication of JP2008501357A publication Critical patent/JP2008501357A/ja
Publication of JP2008501357A5 publication Critical patent/JP2008501357A5/ja
Pending legal-status Critical Current

Links

JP2007526577A 2004-06-10 2005-06-08 遺伝子改変された非ヒト哺乳動物および非ヒト細胞 Pending JP2008501357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0412966.4A GB0412966D0 (en) 2004-06-10 2004-06-10 Genetically modified non-human mammals and cells
PCT/GB2005/050086 WO2005120222A2 (en) 2004-06-10 2005-06-08 Genetically modified non-human mammals and cells

Publications (2)

Publication Number Publication Date
JP2008501357A JP2008501357A (ja) 2008-01-24
JP2008501357A5 true JP2008501357A5 (https=) 2008-07-24

Family

ID=32732258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526577A Pending JP2008501357A (ja) 2004-06-10 2005-06-08 遺伝子改変された非ヒト哺乳動物および非ヒト細胞

Country Status (6)

Country Link
US (3) US8785717B2 (https=)
EP (1) EP1766033B1 (https=)
JP (1) JP2008501357A (https=)
ES (1) ES2535639T3 (https=)
GB (1) GB0412966D0 (https=)
WO (1) WO2005120222A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
ES2631127T3 (es) * 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CN112481302B (zh) * 2021-02-05 2021-05-14 百奥赛图(北京)医药科技股份有限公司 Masp2基因人源化的非人动物的构建方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル, インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
CA2380979A1 (en) 1999-08-13 2001-02-22 Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
JP4764590B2 (ja) 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
RU2003104524A (ru) 2000-07-13 2005-01-20 Дженс Христиан ДЖЕНСЕНИУС (DK) Masp-2, комплемент-связывающий фермент и его применение
US20020094332A1 (en) 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
JP2006502089A (ja) 2002-01-22 2006-01-19 アレクシオン ファーマシューティカルズ, インコーポレイテッド 広範囲の心筋梗塞に対する予防方法
US20060275764A1 (en) 2002-12-03 2006-12-07 Aarhus Universitet Method for determining predisposition to manifestation of immune system related diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
JP2007504805A (ja) 2003-09-05 2007-03-08 ナットイムネ・アクティーゼルスカブ Masp−2結晶構造およびその使用
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
ES2631127T3 (es) 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2

Similar Documents

Publication Publication Date Title
JP6801030B2 (ja) トランスジェニック動物および使用方法
CN105578876B (zh) 制备表达hlai类的非人动物的方法
TWI476280B (zh) 來自二倍體宿主胚胎注射之es-細胞衍生的老鼠
Chiu et al. Transgenic mice that express Cre recombinase in osteoclasts
CN114891797A (zh) T细胞受体基因修饰小鼠
WO2009063722A1 (ja) ヒトチトクロームp450遺伝子(クラスター)を含む哺乳動物人工染色体ベクター及びそれを保持する非ヒト哺乳動物
CN111500628A (zh) CD8定点基因敲入2A-CreERT2-Wpre-pA小鼠模型的构建方法及应用
JP2008501357A5 (https=)
JP2004129649A (ja) 新規なトランスジェニックゼブラフィッシュ、遺伝子断片、及びトランスジェニックゼブラフィッシュの生産方法
CN106978416B (zh) 一种基因定位整合表达系统及其应用
CN103468741B (zh) 改进的由PiggyBac转座子介导的个体基因突变方法
WO2017175745A1 (ja) 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法
JP5481661B2 (ja) 変異導入遺伝子作製方法
CN117417960A (zh) Ighe和fcer1a基因人源化的非人动物及其制备方法和应用
CN100378220C (zh) 用于转基因青鳉鱼的基因片段
US20220217956A1 (en) Rodent Model Of Increased Bone Mineral Density
CN112553194B (zh) Kit基因修饰的非人动物的制备方法和应用
WO2003037081A1 (en) Hcv gene transgenic animal
CN119685331A (zh) 一种LTα人源化基因组及载体和运用
JP4590629B2 (ja) Psf1遺伝子欠損動物およびその利用方法
JP5086074B2 (ja) 白髪発症モデル動物、白髪発症モデル動物の樹立方法、白髪発症モデル動物の継代方法、白髪発症の研究方法、白髪発症制御手段のスクリーニング方法、白髪発症制御用組成物
JPWO2015068411A1 (ja) 遺伝子組み換え非ヒト動物
CN1592576A (zh) 前列腺素e合酶2基因的破环
CN116463376A (zh) Baffr和/或baff基因人源化非人动物的构建方法及应用
JP4940477B2 (ja) Oasis遺伝子欠損マウス